PanGen Biotech Inc.

A222110

KR7222110009

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
5,700 ^KRW	0.00%		-3.88%	-17.15%

Mar. 27	PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI
Mar. 18	PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI

PanGen Biotech Inc. has completed an IPO in the amount of KRW 27.23 billion.

March 09, 2016 at 12:00 am EST

PanGen Biotech Inc. has completed an IPO in the amount of KRW 27.23 billion.

Offer Details:
Security Type: Common Stock
Offered: 1650000
Price/Range: 16500.00

Latest news about PanGen Biotech Inc.

PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	Mar. 26	CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	Mar. 17	CI
PanGen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
PanGen Biotech Inc. announced that it has received KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.	23-04-19	CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.	23-04-17	CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.	22-11-21	CI
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor	21-06-10	CI
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor	21-06-02	CI
Huons Lab Forms Partnership with Pangen Biotech to Co-Develop Human Genetic Recombinant Hyaluronidase	19-12-15	CI
PanGen Biotech Inc.(KOSDAQ:A222110) dropped from S&P Global BMI Index	19-09-23	CI
CCM Duopharma Biotech Berhad completed the acquisition of 8.4% stake in PanGen Biotech Inc. from Chemical Company of Malaysia Berhad.	18-06-28	CI
CCM Duopharma Biotech Berhad entered into agreement to acquire PanGen Biotech Inc. from Chemical Company of Malaysia Berhad for KRW 16.4 billion.	18-04-12	CI
Chemical Companies In Talks To Sell Non Core Assets	18-03-02	CI
PanGen Biotech Inc. announced that it has received KRW 18 billion in funding	18-02-20	CI
PanGen Biotech Inc. announced that it expects to receive KRW 18 billion in funding	18-02-18	CI
PanGen Biotech Inc.(KOSDAQ:A222110) added to S&P Global BMI Index	16-09-19	CI
PanGen Biotech Inc. has completed an IPO in the amount of KRW 27.23 billion.	16-03-09	CI
PanGen Biotech Inc. has filed an IPO in the amount of KRW 18.75 billion.	16-01-22	CI
PanGen Biotech Inc. has withdrawn its IPO in the amount of KRW 35.40 billion.	15-11-24	CI

Pangen Biotech Inc. is a Korea-based company primarily engaged in the bio pharmaceuticals development technology transfer services. The Company mainly provides contract services for the manufacture of bio pharmaceuticals, bio pharmaceuticals development technology transfer services for the manufacture of Chinese hamster ovary (CHO) cell lines and the process of products and gains royalty from the services. The Company also provides reagents which are used for the development of bio pharmaceuticals. In addition the Company is also engaged in the development of bio pharmaceuticals such as Biosimilar EPO, Recombinant Factor VIII and Biosimilar G-CSF. The Company provides its services within domestic market and to overseas markets such as China, India, Mexico, America and Europe.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PANGEN BIOTECH INC.	-17.15%	48.08M
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B

Other Biotechnology & Medical Research